New Delhi, Nov. 4 -- Women's healthcare is attracting growing attention from global investors, and Cinven's latest acquisition is another sign of that shift.

The private equity firm has agreed to acquire Theramex, a pharmaceutical company specializing in women's health, from Carlyle and PAI Partners. The transaction, reportedly valued at approximately €2.6 billion, represents a significant investment in a sector where demand for better treatment options continues to grow.

Why Is Cinven Acquiring Theramex?

For Cinven, the acquisition is about more than expanding its pharmaceutical portfolio. It offers an opportunity to strengthen its position in a healthcare segment that has historically received less attention than many other the...